Visual loss associated with tacrolimus

Case report and review of the literature

Kapil G. Kapoor, Sarah N. Mirza, John A. Gonzales, Syed K. Gibran

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tacrolimus is an immunosuppressive medication in the class of calcineurin inhibitors that acts by inhibiting T-cell and interleukin-2 activity, and is commonly used after allogeneic organ transplant. We present a patient who used tacrolimus after cadaveric kidney transplant and experienced blurry vision. Ocular examination and patient's course subsequently revealed aqueous tear deficiency as a dose-dependent adverse effect of oral tacrolimus.

Original languageEnglish (US)
Pages (from-to)137-139
Number of pages3
JournalCutaneous and Ocular Toxicology
Volume29
Issue number2
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Tacrolimus
Transplants
T-cells
Immunosuppressive Agents
Tears
Interleukin-2
T-Lymphocytes
Kidney

Keywords

  • Aqueous tear deficiency
  • Dry eyes
  • FK506
  • Prograf
  • Tacrolimus

ASJC Scopus subject areas

  • Toxicology

Cite this

Visual loss associated with tacrolimus : Case report and review of the literature. / Kapoor, Kapil G.; Mirza, Sarah N.; Gonzales, John A.; Gibran, Syed K.

In: Cutaneous and Ocular Toxicology, Vol. 29, No. 2, 06.2010, p. 137-139.

Research output: Contribution to journalArticle

Kapoor, Kapil G. ; Mirza, Sarah N. ; Gonzales, John A. ; Gibran, Syed K. / Visual loss associated with tacrolimus : Case report and review of the literature. In: Cutaneous and Ocular Toxicology. 2010 ; Vol. 29, No. 2. pp. 137-139.
@article{8e1f52a62f224eaf81888fae60f11e5a,
title = "Visual loss associated with tacrolimus: Case report and review of the literature",
abstract = "Tacrolimus is an immunosuppressive medication in the class of calcineurin inhibitors that acts by inhibiting T-cell and interleukin-2 activity, and is commonly used after allogeneic organ transplant. We present a patient who used tacrolimus after cadaveric kidney transplant and experienced blurry vision. Ocular examination and patient's course subsequently revealed aqueous tear deficiency as a dose-dependent adverse effect of oral tacrolimus.",
keywords = "Aqueous tear deficiency, Dry eyes, FK506, Prograf, Tacrolimus",
author = "Kapoor, {Kapil G.} and Mirza, {Sarah N.} and Gonzales, {John A.} and Gibran, {Syed K.}",
year = "2010",
month = "6",
doi = "10.3109/15569521003662963",
language = "English (US)",
volume = "29",
pages = "137--139",
journal = "Cutaneous and Ocular Toxicology",
issn = "1556-9527",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Visual loss associated with tacrolimus

T2 - Case report and review of the literature

AU - Kapoor, Kapil G.

AU - Mirza, Sarah N.

AU - Gonzales, John A.

AU - Gibran, Syed K.

PY - 2010/6

Y1 - 2010/6

N2 - Tacrolimus is an immunosuppressive medication in the class of calcineurin inhibitors that acts by inhibiting T-cell and interleukin-2 activity, and is commonly used after allogeneic organ transplant. We present a patient who used tacrolimus after cadaveric kidney transplant and experienced blurry vision. Ocular examination and patient's course subsequently revealed aqueous tear deficiency as a dose-dependent adverse effect of oral tacrolimus.

AB - Tacrolimus is an immunosuppressive medication in the class of calcineurin inhibitors that acts by inhibiting T-cell and interleukin-2 activity, and is commonly used after allogeneic organ transplant. We present a patient who used tacrolimus after cadaveric kidney transplant and experienced blurry vision. Ocular examination and patient's course subsequently revealed aqueous tear deficiency as a dose-dependent adverse effect of oral tacrolimus.

KW - Aqueous tear deficiency

KW - Dry eyes

KW - FK506

KW - Prograf

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=77952177604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952177604&partnerID=8YFLogxK

U2 - 10.3109/15569521003662963

DO - 10.3109/15569521003662963

M3 - Article

VL - 29

SP - 137

EP - 139

JO - Cutaneous and Ocular Toxicology

JF - Cutaneous and Ocular Toxicology

SN - 1556-9527

IS - 2

ER -